Key concepts in biosimilar medicines: What physicians must know

Biologics' are a class of medications produced by living cells using recombinant DNA technology. Biologics have had an important impact in many areas of medicine, and in particular in rheumatology and oncology. However, the high cost of these agents is a growing concern, particularly as more pr...

Full description

Saved in:
Bibliographic Details
Published in:Northern Clinics of Istanbul 2022, Vol.9 (1), p.86-91
Main Author: Iskit, Alper B
Format: Article
Language:English
Subjects:
Adalimumab
Biological products
Inflammatory diseases
Oncology
Review Pharmacology
Rheumatology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Biologics' are a class of medications produced by living cells using recombinant DNA technology. Biologics have had an important impact in many areas of medicine, and in particular in rheumatology and oncology. However, the high cost of these agents is a growing concern, particularly as more products become available and their use for the treatment of immune-mediated inflammatory diseases continues to expand. Biosimilars, also called follow-on biologics, have been viewed as a potential cost-saving alternative to traditional therapies. Currently, a product can be considered biosimilar to a reference product if there are no clinically meaningful differences in terms of safety, purity, and potency. In this review, the most important key concepts about biosimilars were summarized for physicians emphasizing the status in Turkey.
ISSN:2148-4902
2149-4902
2536-4553
DOI:10.14744/nci.2021.84669